Astralis Ltd., partnered with SkyPharma PLC, has initiated a phase I clinical trial in the United States for Psoraxine, a new injectable treatment for moderate psoriasis.
Previewing Fall Clinical PA & NP Conference With James Del Rosso, DO
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Janssen Announces Positive Results From Guselkumab Psoriatic Arthritis Trial
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Pointers With Portela: Products to Build a Skin Care Routine
Michael Cameron, MD, FAAD, Shares Challenges, Insights Into Opening a New Practice
2 Clarke Drive Cranbury, NJ 08512